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pulmonary edema. Hemodialysis was initiated and continued
throughout her admission. Renal ultrasound showed normal
kidney size with echogenicity consistent with parenchymal dis-
ease. Serologic tests were ordered and a renal biopsy was per-
formed.
The renal biopsy demonstrated involvement of essentially
all glomeruli by necrosis, sclerosis, or both. Approximately 90%
of glomeruli had cellular or fibrocellular crescents (Fig. 1A).
There was focal disruption of Bowman’s capsule. Most glomer-
uli had prominent adjacent periglomerular inflammation, in-
cluding occasional multinucleated giant cells. A few small foci
of granulomatous inflammation were present but were cen-
tered on identifiable glomeruli (Fig. 1C). Arteries and arteri-
oles had moderate sclerosis as well as focal necrotizing vasculi-
tis (Fig. 1D). Immunofluorescence microscopy demonstrated
intense linear staining of glomerular basement membranesCASE PRESENTATION
(GBMs) for immunoglobulins (IgG) (Fig. 1B), kappa light
A 77-year-old white woman was found unresponsive on the chains, and lambda light chains, and moderate granular staining
floor of her home. Emergency medical technicians were called, for C3. There was no staining for IgA, IgM, or C1q. There was
and she was transported to the University of North Carolina marked staining of crescents for fibrin. Electron microscopy
Hospitals. She recovered consciousness and gave a history of revealed extensive disruption of glomerular basement mem-
recent anorexia, lower extremity weakness and paresthesias, branes and Bowman’s capsule, segmental fibrinoid necrosis,
and difficulty walking. Her medical history was significant for and no immune-complex-type electron-dense deposits.
rectal adenocarcinoma 9 years earlier that was successfully Serology demonstrated the presence of high-titer myelo-
treated with radiation, chemotherapy, and partial colectomy. peroxidase-specific antineutrophil cytoplasmic autoantibodies
A recent colonoscopy showed no recurrence. She had been (MPO-ANCA) and high-titer anti-GBM antibodies. Testing for
diagnosed with a myeloproliferative disorder with features of proteinase 3–specific ANCA (PR3-ANCA) and antinuclear
essential thrombocytosis, and hydroxyurea (500 mg/day) had autoantibodies (ANA) was negative.
been initiated. The patient received hemodialysis, plasmapheresis, and pulse
Physical examination revealed an elderly, thin, lethargic methylprednisolone. Cyclophosphamide was not instituted be-
woman who was afebrile and had a blood pressure of 140/60 cause of the poor prognosis for recovery of renal function and
mm Hg, guaiac-negative stool, no rash, 1 pitting edema to the overall frail status of the patient. During the entire 3-week
the knees, and bilateral foot drop. Computerized tomography admission, she produced less than 50 mL urine/day. Her lower
(CT) identified a small subdural hematoma. Laboratory data extremity neuropathy improved and her lungs cleared. After
included blood urea nitrogen (BUN), 158 mg/dL; serum creati- Permacath placement, she was discharged to a nursing home
nine, 10.8 mg/dL (0.6 mg/dL 2 months prior to admission); on low-dose oral prednisone and scheduled to receive hemodi-
potassium, 6.3 mmol/L; glucose, 101 mg/dL; albumin, 2.3 g/dL; alysis.
white blood cell count, 23.3  109/L (neutrophil count, 19.3 
109/L); red blood cell count, 3.5  1012/L; and platelet count,
799  109/L. Urinalysis revealed 2 protein, 4 blood, and nu- DISCUSSION
merous dysmorphic red blood cells. Chest radiographs showed
Dr. J. Charles Jennette (Brinkhous Distinguished
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gressive glomerulonephritis clinically and crescentic glo-Key words: renal failure, immune-complex disease, ANCA, pauci-
immune disease. merulonephritis pathologically. Volhard and Fahr [1] re-
ported this correlation between clinically severe renal 2003 by the International Society of Nephrology
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Fig. 1. Pathologic findings in the renal biopsy specimen. (A) Glomerular cellular crescents with fragmentation of the glomerular tuft (arrows)
(periodic acid-Schiff stain, 600). (B) Linear staining of glomerular basement membranes for IgG showing numerous breaks in the basement
membrane (arrow) (FITC anti-IgG stain, 600). (C ) Focal periglomerular, interstitial granulomatous inflammation with multinucleated giant cells
(arrows) (Jones silver methenamine stain, 600). (D) Necrotizing arteritis with fibrinoid necrosis (arrow) and surrounding infiltration by predomi-
nantly neutrophilic leukocytes (periodic acid-Schiff stain, 600).
disease and glomerular crescents in 1914. They called chronic sequelae. Current therapy is relatively crude and
employs nonspecific and toxic anti-inflammatory and im-the clinical expression “subacute nephritis” and the renal
lesion “extracapillary nephritis.” In 1942, Ellis [2] referred munosuppressive agents. A better understanding of the
pathophysiology of crescentic glomerulonephritis shouldto this aggressive category of glomerulonephritis as “rap-
idly progressive type I nephritis” and provided a photo- lead to more effective, more specific, and less toxic thera-
pies.micrograph of a glomerulus with “epithelial crescent for-
mation” to illustrate the underlying pathologic lesion. The patient described exemplifies an unfortunate pre-
sentation and outcome because the crescentic glomeru-Crescentic glomerulonephritis must be diagnosed
promptly and precisely so that appropriate treatment lonephritis was far advanced when first recognized and
thus not responsive to treatment. The glomerulonephri-can be initiated as quickly as possible. The best predictor
of outcome for all types of crescentic glomerulonephritis tis itself illustrates an uncommon but well-recognized
concurrence of circulating ANCA and anti-GBM anti-is the severity of renal failure at the time therapy begins.
Even several days’ delay in diagnosis and treatment can bodies in a patient with crescentic glomerulonephritis.
have a major negative impact on outcome because of the
Immunopathologic categoriesrapidly progressing loss of renal function that typically
accompanies crescentic glomerulonephritis. Requirements The pathology and immunopathology of crescentic glo-
merulonephritis comprise three major categories: (1) anti-for satisfactory management include a proper index of sus-
picion by the physician who first encounters the patient, GBM crescentic glomerulonephritis, (2) immune-com-
plex crescentic glomerulonephritis, and (3) pauci-immuneprompt referral to a nephrologist, timely and accurate clini-
cal and pathologic diagnosis, rapid institution of appro- crescentic glomerulonephritis [3, 4]. Unlike immune-
complex glomerulonephritis and anti-GBM glomerulo-priate immunosuppressive therapy, and proper long-term
management of persistent or recurrent disease and its nephritis, pauci-immune crescentic glomerulonephritis
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Table 1. Frequency of different types of crescentic glomerulonephritis in consecutive native renal biopsy specimens evaluated by the
University of North Carolina Nephropathology Laboratory
Pauci-immune crescentic Immune-complex crescentic Anti-GBM crescentic Other crescentic
glomerulonephritisa glomerulonephritisb glomerulonephritisc glomerular diseased
All (N  632) 60% 377/632 24% 154/632 15% 92/632 1% 9/632
Age 1 to 20 years (N  73) 42% 31/73 45% 33/73 12% 9/73 0% 0
Age 21 to 60 years (N  303) 48% 145/303 35% 106/303 15% 44/303 3% 8/303
Age 61 to 100 years (N  256) 79% 201/256 6% 15/256 15% 39/256 0% 1/256
a Pauci-immune crescentic glomerulonephritis was defined as glomerulonephritis with 50% or more crescents and 2 or less staining of glomeruli for any
immunoglobulin
b Immune-complex crescentic glomerulonephritis was defined as glomerulonephritis with 50% or more crescents and greater than 2 nonlinear glomerular staining
for any immunoglobulin by direct immunofluorescence microscopy (plus membranoproliferative and postinfectious glomerulonephritis)
c Anti-GBM crescentic glomerulonephritis was defined as glomerulonephritis with 50% or more crescents and 2 or greater linear GBM staining for immunoglobulins
by direct immunofluorescence microscopy
d The “other” category includes all other glomerular diseases with 50% or more crescents, such as thrombotic microangiopathy, diabetic glomerulosclerosis, and
monoclonal immunoglobulin deposition disease
by definition has an absence or paucity of glomerular immune or ANCA-associated crescentic glomerulo-
nephritis have systemic small-vessel vasculitis [6–9]. Thestaining for immunoglobulins [4, 5]. In approximately
80% of patients, pauci-immune crescentic glomerulo- pauci-immune glomerulonephritis in patients with no ev-
idence for systemic vasculitis sometimes is called “renal-nephritis is associated with ANCA and thus can be called
ANCA-associated crescentic glomerulonephritis [4, 6]. limited vasculitis” because it is pathologically identical
to the glomerulonephritis in patients with concurrentA few patients with crescentic glomerulonephritis have
concurrent expression of more than one immunopatho- vasculitis elsewhere. The three clinicopathologic catego-
ries of ANCA-associated, systemic, small-vessel vasculi-logic phenotype. Approximately one-half of patients with
anti-GBM glomerulonephritis have pulmonary capillar- tis are microscopic polyangiitis, Wegener’s granulomato-
sis, and Churg-Strauss syndrome [7]. A diagnosis ofitis (Goodpasture’s syndrome), and approximately three-
fourths of patients with ANCA-glomerulonephritis have microscopic polyangiitis is appropriate in the setting of
small-vessel vasculitis with no evidence for granuloma-systemic small-vessel vasculitis (for example, microscopic
polyangiitis or Wegener’s granulomatosis). Immune-com- tous inflammation or asthma. A diagnosis of Wegener’s
granulomatosis is appropriate if granulomatous inflam-plex crescentic glomerulonephritis has the lowest fre-
quency of systemic vasculitis, although it can occur (for mation is present (usually in the respiratory tract) but
not asthma. Finally, a diagnosis of Churg-Strauss syn-example, with Henoch-Schönlein purpura). Also, some
patients have overlap between immunopathologic phe- drome is appropriate with granulomatous inflammation,
eosinophilia, and asthma. For the diagnostic categoriza-notypes. For example, approximately one-fourth to one-
third of patients with anti-GBM glomerulonephritis have tion of systemic vasculitis, periglomerular granuloma-
tous inflammation does not fulfill the granulomatous in-ANCA as well, like the patient presented today.
In a patient with rapidly progressive glomerulonephri- flammation criterion.
In patients with ANCA-associated glomerulonephri-tis, statistically the most likely diagnosis is ANCA-associ-
ated pauci-immune crescentic glomerulonephritis unless tis, most ANCA have specificity for MPO or PR3, which
are proteins in the primary granules of neutrophils andthe patient is a child (Table 1). In children, immune-
complex crescentic glomerulonephritis is most common the lysosomes of monocytes [6]. Patients with Wegener’s
granulomatosis have the highest frequency of PR3-ANCA,because of the combined effect of less-frequent ANCA
disease and a higher frequency of most types of immune- and patients with renal-limited disease have the highest
frequency of MPO-ANCA [6–9].complex glomerulonephritis, including acute post-strep-
tococcal glomerulonephritis, Henoch-Schönlein purpura Anti-GBM glomerulonephritis is the most aggressive
form of glomerulonephritis, with the highest frequencynephritis, IgA nephropathy, membranoproliferative glo-
merulonephritis, and lupus nephritis. ANCA glomerulo- of renal insufficiency and the highest frequency of cres-
cent formation at the time of diagnosis (Tables 2 andnephritis is by far the most common cause of rapidly
progressive glomerulonephritis in adults, especially older 3). More than 95% of patients with anti-GBM glomeru-
lonephritis have crescents at the time of biopsy, andadults. Approximately 80% of crescentic glomerulo-
nephritis in patients over 60 years of age is pauci-immune approximately 85% have 50% or more of glomeruli with
crescents (Table 3). ANCA glomerulonephritis is a closedisease, which is associated with ANCA approximately
80% of the time. Anti-GBM disease is uncommon at second; approximately 90% of patients have crescents,
and approximately 50% have 50% or more of glomeruliany age.
Approximately three-fourths of patients with pauci- with crescents. In contrast, all types of immune-complex
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Table 2. Features of different types of crescentic glomerulonephritis evaluated by the
University of North Carolina Nephropathology Laboratorya
Mean age Creatinine Proteinuria
range Male:female Black:Whiteb mg/dL (range) g/24 hours (range)
Anti-glomerular basement 5221 (14 to 84) 1.0:1.0 45:47 1.0:9.0 7:63 9.7 7.2 (0.8 to 50) 1.67 3.35 (0.20 to 16.20)
membrane (GBM) cres- N  92 N  92 N  70 N  86 N  68
centic glomerulonephritis
Pauci-immune crescentic 5620 (2 to 92) 1.0:0.9 202:177 1.0:3.7 65:239 6.5 4.0 (0.8 to 22.1) 1.94 2.95 (0.11 to 18.00)
glomerulonephritis N  377 N  379 N  304 N  338 N  331
Immune-complex crescentic 3317 (4 to 77) 1.0:1.6 61:95 1.0:0.9 67:62 4.9 3.8 (0.8 to 21.7) 4.39 4.77 (0.30 to 22.00)
glomerulonephritis N  154 N  156 N  129 N  145 N  136
a Anti-GBM crescentic glomerulonephritis, pauci-immune crescentic glomerulonephritis, and immune-complex crescentic glomerulonephritis were defined as
detailed in Table 1
b Approximate black:white ratio in the referral population is 1:3
Table 3. Frequency of glomerular crescents, necrosis, and endocapillary hypercellularity in different types of glomerular disease evaluated
by the University of North Carolina Nephropathology Laboratory
Average % Glomerular Glomerular
% with any % with 50% glomerular necrosis hypercellularityc
Type of glomerular disease Number crescents crescents crescentsb (0 to 4) (0 to 4)
Anti-GBM glomerulonephritis 105 97.1 84.8 77 1.7 0.8
ANCA glomerulonephritisa 181 89.5 50.3 49 1.2 0.8
Lupus glomerulonephritis (III & IV) 784 56.5 12.9 31 1.7 2.2
H-S purpura glomerulonephritis 31 61.3 9.7 27 0.4 1.5
IgA nephropathy 853 32.5 4.0 21 0.1 1.4
Post-infectious glomerulonephritis 120 33.3 3.3 19 0.3 2.7
Type I membranoproliferative
glomerulonephritis 307 23.8 4.6 25 0.2 2.8
Type II membranoproliferative
glomerulonephritis 16 43.8 18.8 48 0.2 1.8
Fibrillary glomerulonephritis 101 22.8 5.0 26 0 0.6
Monoclonal immunoglobulin
deposition disease 54 5.6 0 13 0 0.3
Thrombotic microangiopathy 251 5.6 0.9 26 0.4 0.3
Diabetic glomerulosclerosis 648 3.2 0.3 20 0 0.3
Nonlupus membranous
glomerulopathy 1092 3.2 0.1 15 0.0 0.1
aANCA glomerulonephritis was defined as glomerulonephritis with 2 or less staining of glomeruli for any immunoglobulin in a patient who is positive for MPO-
ANCA or PR3-ANCA by ELISA
bAverage % of glomeruli with crescents when crescents were present
cEndocapillary (not extracapillary) hypercellularity
glomerulonephritis have a much lower frequency of cres- ity of ANCA-associated small-vessel vasculitis as well as
anti-GBM antibody-mediated Goodpasture’s syndrome.cent formation and, when crescents are present, they
rarely affect 50% or more of glomeruli. The most common cause of pulmonary-renal syndrome
is ANCA-associated small-vessel vasculitis, such as mi-Patients with anti-GBM disease can have anti-GBM
glomerulonephritis alone or in combination with anti- croscopic polyangiitis or Wegener’s granulomatosis. In
a study of patients with pulmonary-renal syndrome, NilesGBM, antibody-mediated pulmonary hemorrhage (Good-
pasture’s syndrome). Approximately 40% to 60% of et al [15] found that 54% had ANCA, 7% had ANCA
and anti-GBM antibodies, and 6% had anti-GBM alone.patients with anti-GBM disease have pulmonary hemor-
rhage [10, 11]. Other factors such as pulmonary alveolar The best laboratory predictors of pauci-immune cres-
centic glomerulonephritis and anti-GBM crescentic glo-capillary damage by cigarette smoke or other hydrocar-
bon exposure might predispose patients to lung involve- merulonephritis are serologic detection of ANCA or
anti-GBM antibodies, respectively [6–9, 16–18]. The bestment [12, 13]. Cigarette smoke likely predisposes to lung
involvement via oxidant-induced neutralization of alveo- laboratory predictors of immune-complex crescentic glo-
merulonephritis are various serologic markers for differ-lar alpha 1-antiproteinase and resultant greater suscepti-
bility to capillary injury by unopposed proteinases re- ent types of immune-complex disease, for example, hypo-
complementemia, antinuclear antibodies, cryoglobulins,leased by activated leukocytes [14].
Glomerulonephritis accompanied by pulmonary hem- or antibodies indicative of a potentially nephritogenic
infection. At the University of North Carolina, 78% oforrhage (pulmonary-renal syndrome) raises the possibil-
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Table 4. Comparison of pathologic and clinical features of glomerulonephritis in patients (with complete serologic data and glomerulonephritis
with or without crescents) with different ANCA and anti-glomerular basement membrane (GBM) serology findings evaluated by the
University of North Carolina Nephropathology Laboratory
MPO-ANCA positive, PR3-ANCA positive, ANCA positive, ANCA negative,
anti-GBM negative anti-GBM negative anti-GBM positive anti-GBM positive
N  102 N  52 N  25 N  28
50% crescents, % 44 38 62 93
Mean % crescentsa 4829 4630 67 32 84 21
Glomerular necrosisb 1.2 1.8 2.1 2.1
Glomerular sclerosisb 1.7 1.3 1.2 1.1
Age 6215 5418 6813 4121
Male:female 1.0:0.9 1.0:0.7 1.0:1.1 1.0:0.9
Black:Whitec 1.0:6.1 1.0:23.8 1.0:9.0 1.0:4.9
Creatinine 6.97.7 5.6 4.6 9.6 5.3 10.0 9.1
Anti-GBM titer 20 20 350.5 579.7
ANCA titer 86.022 92.9 39 72.3 25 20
a Mean % crescents when crescents are present
b Mean of scores of 0 to 4 with 0 none and 4 severe
c Approximate black:white ratio in the entire renal biopsy population is 1:3
patients with pauci-immune crescentic glomerulonephri- induce ANCA and pauci-immune crescentic glomerulo-
nephritis [6, 32, 33]. Our patient today received hydroxy-tis had MPO-ANCA or PR3-ANCA detectable by en-
zyme-linked immunosorbent assay (ELISA) (unpublished urea for a myeloproliferative disorder. Although hy-
droxyurea is molecularly related to hydralazine, I amdata). Conversely, 87% of patients with renal biopsy
findings consistent with anti-GBM disease had detect- not aware of previous reports of hydroxyurea inducing
ANCA. The association between myeloproliferative dis-able antibodies to the noncollagenous domain of type IV
collagen (anti-NC1). Some of the 13% of patients with orders and the development of glomerulonephritis, small
vessel vasculitis, and ANCA is poorly defined [34–36].linear GBM IgG but negative assay for anti-NC1 might
have had antibodies directed against other antigens in The link has been observed primarily with myelodysplas-
tic disease or overt myeloid leukemia rather than withthe GBM, such as entactin [16, 19]. The small minority
of patients with pauci-immune crescentic glomerulone- the type of myeloproliferative disease present in the pa-
tient we are discussing.phritis who do not have detectable MPO-ANCA or PR3-
ANCA may have other etiologic agents that produce
Natural history, treatment, and outcomethe same final common pathway of glomerular vascular
injury, for example, ANCA with specificities that are not Current therapy and supportive management have
dramatically improved the outcome of rapidly progres-detected by current assays.
The patient under discussion today had both anti- sive crescentic glomerulonephritis. Still, there is substan-
tial need for further improvement. The prognosis andGBM and ANCA antibodies. This is a well-recognized
concurrence that occurs in about one-fourth to one-third appropriate treatment for crescentic glomerulonephritis
vary depending on the immunopathologic category andof patients with anti-GBM antibodies and in a much
smaller proportion of patients with ANCA (Table 4) disease severity at the time treatment is begun. Anti-
GBM and ANCA glomerulonephritis are so aggressive[20–31]. ANCA can be detected before or after anti-
GBM antibodies. Anti-GBM antibodies are much more that even patients with little or no crescent formation
should be considered for substantial immunosuppressiveoften accompanied by MPO-ANCA than by PR3-ANCA.
The anti-GBM and ANCA are two separate populations treatment, especially if pulmonary involvement is pres-
ent. On the other hand, some categories of immune com-of antibodies rather than one cross-reacting population
[26]. The anti-GBM antibodies that occur with ANCA plex glomerulonephritis, such as IgA nephropathy and
acute postinfectious glomerulonephritis, do not neces-have the same specificity for the noncollagenous domain
of type IV collagen as do anti-GBM antibodies that occur sarily warrant extensive immunosuppressive therapy un-
less numerous active crescents are present.without ANCA [28]. The concurrence of ANCA and
anti-GBM antibodies is too frequent to be a coincidence; A strong predictor of outcome for all types of cres-
centic glomerulonephritis is the severity of renal insuffi-however, the cause is unknown.
Today’s patient had a myeloproliferative disorder and ciency at the time treatment is begun [6, 37–39]. The
pathologic severity, activity, and chronicity of glomerularhad received a variety of drugs prior to developing ANCA
and anti-GBM antibodies. Certain drug exposures are and tubulointerstitial disease can help refine the prog-
nosis. For example, in patients with ANCA crescenticknown to induce multiple autoantibodies, including ANCA
[6]. For example, hydralazine and propylthiouracil can glomerulonephritis, a higher proportion of histologically
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unaffected glomeruli correlates with increased renal sur- phritis include leflunomide, deoxyspergualin, tumor ne-
vival [40]. The serologic profile correlates in general with crosis factor (TNF) blockade, calcineurin inhibitors, and
presentation and outcomes in patients with ANCA, anti- antibodies against T cells. A better understanding of the
GBM antibodies, or both. Patients who are anti-GBM pathophysiology of crescentic glomerulonephritis could
positive and ANCA negative have more severe disease suggest additional therapeutic options.
at diagnosis (Table 4) and worse outcome [23] than do
Can the pathophysiology of crescent formation offerpatients with positive ANCA and negative anti-GBM.
hints for better treatment?Counterintuitively, patients with both anti-GBM and
ANCA have less extensive crescent formation (Table 4) The cellular and molecular mechanisms that lead to
and better prognosis [23] than do patients who have anti- crescent formation are incompletely known. As noted
GBM without ANCA. Compared to patients with PR3- earlier, multiple etiologies and pathogenetic mechanisms
ANCA, patients with MPO-ANCA have more “chronic- can initiate crescent formation, including immune com-
ity” and less “activity” (pathologically) at the time of plexes, anti-GBM antibodies or T cells, and ANCA [41].
diagnosis (Table 4) [41] and have better long-term renal All these initiating mechanisms might lead to a final com-
survival [9, 16]. These average differences are not great mon pathway of injury that involves extensive disruption
enough to significantly affect treatment or prognosis in of glomerular capillary walls. This raises the possibility
individual patients. that a critical step in this common pathway might be
The standard treatment for anti-GBM glomerulo- amenable to treatment that would be effective in multi-
nephritis, ANCA glomerulonephritis, and severe cres- ple kinds of crescentic glomerulonephritides.
centic immune complex glomerulonephritis (for exam- Glomerular immune-complex localization appears to
ple, crescentic lupus nephritis) is high-dose corticosteroids be less effective at inducing crescent formation than are
and cytotoxic immunosuppressive drugs [3, 6, 38, 39]. ANCA or anti-GBM antibodies (Table 3). When immune-
Plasmapheresis is added for anti-GBM glomerulonephri- complex glomerulonephritis has crescents, immune com-
tis and for ANCA glomerulonephritis that is accompa- plexes usually are identifiable in subendothelial loca-
nied by pulmonary hemorrhage. Levy et al [38] found tions, where they are in close proximity to humoral and
that the 1-year patient and renal survival rates for anti- cellular inflammatory mediator systems in the blood. For
GBM glomerulonephritis are 100% and 95%, respec- example, electron microscopy demonstrates that patients
tively, if immunosuppression and plasma exchange are who have lupus nephritis or IgA nephropathy with cres-
begun when the serum creatinine is less than 5.7 mg/dL. cents frequently have subendothelial immune-complex
If the serum creatinine is 5.7 mg/dL or higher, the 1-year
deposits, whereas patients with only mild glomerular
patient and renal survival rates are 83% and 82%, respec-
inflammation without crescents typically have exclu-tively, if dialysis is not necessary initially, but only 65%
sively mesangial immune-complex deposits [4]. Immuneand 8%, respectively, if dialysis is required.
complexes in the subendothelial zone are in an oppor-The exact regimen of immunosuppression for ANCA-
tune location to attract and activate neutrophils andassociated crescentic glomerulonephritis continues to be
monocytes, which are then in a prime location to causerefined [6, 39]. Of particular note is the well-organized
maximal glomerular capillary wall injury.prospective study of an array of treatment regimens for
Well over 3 decades ago, Lerner, Glassock, and DixonANCA glomerulonephritis that is being carried out by
established that anti-GBM antibodies cause glomerulo-the European Vasculitis Study Group [6, 39]. Cyclophos-
nephritis by showing that anti-GBM antibodies from hu-phamide remains the drug of choice for induction of
mans cause glomerulonephritis when injected into mon-remission. Current immunosuppressive regimens that
keys [42]. Anti-GBM antibodies have specificity for thecombine high-dose corticosteroids and cyclophospha-
C-terminal noncollagenous globular domain of the 3mide induce remission in more than 90% of patients
chain of type IV collagen [43]. A variety of animal models[39]. Approximately one-fourth to one-third of patients
of glomerulonephritis are induced by heterologous orexperience a recurrence within several years. The need
autologous anti-GBM antibodies, and several modelsfor maintenance immunosuppression therapy raises the
support a role for anti-GBM T lymphocytes [44]. Twoproblem of adequate immunosuppression versus toxic-
interesting studies by Wu et al [45, 46] provide some ofity. Cyclophosphamide has been used extensively in the
the strongest evidence that anti-GBM T lymphocytespast, but other remission-maintenance agents being eval-
cause glomerulonephritis. This group induced glomeru-uated include azathioprine and mycophenolate mofetil
lonephritis both by active immunization with an antigen[39]. The goal should be to reduce toxicity while main-
that elicited a predominantly T-cell response [45] andtaining a recurrence rate of less than 20% at 2 years.
by passive transfer of T lymphocytes specific for rat re-Additional therapeutic agents that might prove valuable
combinant noncollagenous domain of collagen IV 3in the treatment of ANCA-associated glomerulonephri-
tis as well as in other forms of crescentic glomerulone- chain [46].
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In vitro experiments have demonstrated that ANCA formation even without basement membrane disruption
[59].IgG can activate cytokine-primed neutrophils by inter-
The cells in crescents are predominantly epithelialacting with MPO or PR3 at the surface of the cells [6, 47].
cells and macrophages [59–63]. The relative proportionNeutrophils that have been activated by ANCA release
of epithelial cells to macrophages varies, depending onlytic proteinases, toxic oxygen products, and inflamma-
the age of the crescent and the integrity of Bowman’story cytokines, and these neutrophils can adhere to and
capsule [59–63]. Epithelial cells predominate when Bow-kill endothelial cells in culture [6, 47]. This sequence of
man’s capsule is intact, whereas macrophages predomi-events occurring in vivo could cause glomerulonephritis
nate when Bowman’s capsule is disrupted [63]. Ruptureand small-vessel vasculitis. A mouse model of MPO-
of Bowman’s capsule allows monocytes and macro-ANCA glomerulonephritis confirms that MPO-ANCA
phages to enter not only from the capillary blood butcan cause pauci-immune glomerulonephritis with necro-
also from the periglomerular interstitium. Periglomeru-sis and crescents, a lesion that closely resembles human
lar inflammation, including granulomatous inflammationANCA glomerulonephritis [48]. This model is induced
with multinucleated giant cells, seen in the patient underby injecting anti-MPO IgG produced in MPO knockout
discussion, is most common when Bowman’s capsule ismice into immune-deficient mice that have no function-
ruptured [64]. Periglomerular granulomatous inflamma-ing B or T lymphocytes of their own. The recipient mice
tion is not specific because it can be seen with any typedevelop pauci-immune focal necrotizing and crescentic
of severe necrotizing glomerulonephritis, including bothglomerulonephritis, pulmonary capillaritis, and necrotiz-
anti-GBM disease and any type of ANCA disease [4, 64].ing arteritis within 1 week. This model shows that ANCA
Within 1 week or so, cellular elements in crescents beginIgG can cause glomerulonephritis and small-vessel vas-
to disappear through apoptosis [65], and collagen accu-culitis in the absence of antigen-specific T lymphocytes.
mulates as a result of synthesis by epithelial cells [66] andThe anti-MPO IgG also causes pauci-immune focal nec-
fibroblasts that infiltrate through breaks in Bowman’srotizing and crescentic glomerulonephritis and systemic
capsule [67]. The transition from cellular to fibrotic cres-vasculitis in immune-competent wild-type mice [48].
cent might be orchestrated, at least in part, by trans-How do immune complexes, anti-GBM antibodies or
forming growth factor-beta (TGF-), which inhibits epi-T lymphocytes, and ANCA initiate the inflammatory
thelial proliferation and promotes fibrosis [68].glomerular injury that culminates in crescent formation?
As noted earlier, the glomerular injury that appearsIn 1956, Rich at Johns Hopkins proposed that crescents
most effective at initiating crescent formation is ruptureare produced by the proliferation of glomerular epithe-
of capillary basement membranes, which allows plasmalial cells in coagulated blood that has spilled into Bow-
and inflammatory mediators into Bowman’s space. This
man’s space [49]. This concept is in accord with later
influx can only occur in the presence of lysis of the GBM.
observations that crescents contain fibrin and that inter- Type IV collagen, laminin, fibronectin, and proteogly-
ference with fibrin formation in experimental animal cans are major components of the GBM. Thus, agents
models of crescentic glomerulonephritis eliminates or that lyse these proteins and are released during glomeru-
reduces crescent formation [4, 44, 49– 54]. The fibrin is lar inflammation are likely important participants in the
derived from plasma coagulation factors that spill into induction of crescentic glomerulonephritis. Prime candi-
Bowman’s space through breaks in glomerular capillar- dates include serine proteinases and matrix metallopro-
ies. Scanning electron microscopy shows numerous irreg- teinases (MMPs) that can degrade type IV collagen, lam-
ular perforations of GBMs in specimens with crescentic inin, fibronectin, and proteoglycans [69, 70]. Activated
glomerulonephritis [55]. The coagulation factors form neutrophils and monocytes, which are ubiquitous in early
fibrin after they come in contact with tissue factor and crescentic glomerulonephritis of all types, release serine
other thrombogenic materials in Bowman’s space [56–57]. proteinases and MMPs. Perturbed glomerular endothe-
Persistence of fibrin in Bowman’s space is facilitated by lial, epithelial, and mesangial cells also release MMPs.
plasminogen activator inhibitor (PAI-1) [53, 57]. Most proteinases are secreted as pro-enzymes that re-
Activated coagulation factors and inflammatory cyto- quire molecular modification to become active. Notable
kines that enter Bowman’s space in crescentic glomeru- exceptions are the major serine proteinases (elastase,
lonephritis cause endogenous glomerular cells and infil- PR3, and cathepsin G) that are stored in active form
trating leukocytes to release many cytokines that stimulate within cytoplasmic granules of neutrophils and mono-
the influx of macrophages and the proliferation of epithe- cytes, and which are released at sites of leukocyte activa-
lial cells; this process leads to crescent formation [44, 58]. tion [69, 70]. These serine proteinases can degrade type
Although breaks in GBMs and fibrin in Bowman’s space IV collagen, laminin, fibronectin, and proteoglycans (in-
appear to provide a strong impetus to crescent formation, cluding heparin sulfate). They all are highly cationic and
intense inflammation within glomeruli with intact base- active at neutral pH and thus can attach to and degrade
basement membranes at plasma pH. Elastase might bement membranes might be capable of inciting crescent
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the most important proteinase in basement membrane ase inhibitors and also activate latent metalloproteinase
pro-enzymes.lysis. It also has many inflammatory effects, such as acti-
vation of cytokines and induction of endothelial and Thus, oxidants, serine proteinases, and metallopro-
teinases together create a local milieu that can kill glo-epithelial cells to secrete cytokines [69]. Elastase and
PR3 also kill cells [71], and thus they can destroy not only merular cells and dissolve GBMs. This toxic and lytic
microenvironment is very localized, however, becausethe capillary basement membranes but also glomerular
endothelial and epithelial cells. beyond the oxidant shield the serine proteinases are not
protected from neutralization and the MMP pro-enzymesThe destructive potential of serine proteinases is re-
flected in the fact that approximately 10% of plasma pro- are not activated.
Using in vitro experiments, Donavan et al have docu-teins are serine proteinase inhibitors, such as 1-protein-
ase inhibitor. Serine proteinases also are inhibited by mented the ability of elastase to degrade GBM, as well
as the ability of oxidants to abolish the inhibitory affect2-macroglobulin, which is a broad-spectrum antipro-
teinase that also inhibits cysteine proteinases, aspartic of alpha 1-antiproteinase on elastase-mediated GBM
degradation [72]. The in vivo relevance of these in vitroproteinases, and MMPs. At sites of inflammatory injury,
serine proteinases are protected from neutralization by studies is supported by the presence of elastase [73] and
PR3 [74] at sites of glomerular necrosis in crescenticantiproteinases by multiple mechanisms, including neu-
tralization of antiproteinases by oxidants (especially hy- glomerulonephritis. Further, MMPs, including MT-MMPs,
have been identified in glomerular crescents [75].pochlorous acid generated by leukocyte respiratory
bursts), high concentration of proteinases and exclusion A number of experimental animal models indicate
that T lymphocytes play an important role in crescentof antiproteinases in the microenvironment between leu-
kocytes and tissue (for example, between leukocytes and formation [44–46]. If this is the case, T lymphocytes
must have a direct or indirect mechanism for degradingGBM), and resistance to inhibition when bound to cell
surfaces (for example, leukocyte cell membranes) or tis- GBMs. T lymphocytes can degrade collagen directly
sue (for example, GBM). Elastase that is bound to the through the production of MMPs [76]. Granzymes re-
surface membrane of neutrophils and monocytes is not leased by T lymphocytes are serine proteinases that are
only particularly effective at lysis of type IV collagen cytotoxic and can lyse proteoglycans; however, gran-
but also is protected from inactivation by proteinase zymes alone are not effective at lysing GBM because
inhibitors [69, 70]. they do not degrade collagen or laminin [69]. Activated
Matrix metalloproteinases are produced by leukocytes T lymphocytes also can cause GBM degradation indi-
and many other cell types. Some, but not all, MMPs rectly by stimulating MMP production by endogenous
can degrade type IV collagen, laminin, fibronectin, and glomerular cells and by inducing release of serine pro-
proteoglycans. Synthesis of MMPs in leukocytes and en- teinases and MMPs by neutrophils and monocytes. This
dogenous glomerular cells is up-regulated after stimula- latter mechanism is the most likely means for T lympho-
tion by inflammatory mediators [69, 70]. However, cytes to cause substantial matrix lysis.
MMP-8 (collagenase) and MMP-9 (gelatinase) are ex- Animal data addressing the therapeutic efficacy of re-
ceptions because they are synthesized in advance and combinant or synthetic proteinases in glomerulonephri-
stored in neutrophil and monocyte granules for rapid tis are limited. In a study of immune-complex–mediated
release during acute inflammation. As monocytes trans- glomerulonephritis in mice, intraperitoneal administra-
form into macrophages, they shift from releasing pre- tion of a synthetic serine proteinase inhibitor markedly
dominantly serine proteinases to releasing predomi- reduced glomerular necrosis even though immune-com-
nantly MMPs [69]. The MMPs are released as pro- plex deposition and endocapillary hypercellularity were
enzymes that must be activated by serine proteinases, not reduced [77]. This at least supports the possibility
oxidants (for example, hypochlorous acid), or active that proteinase inhibitors could be useful in the treat-
MMPs. Membrane-type MMPs (MT-MMPs) appear to ment of necrotizing glomerulonephritis.
be particularly important for the activation of some pro-
MMPs. MMPs are inhibited by 2-macroglobulin and
CONCLUSIONby tissue inhibitors of MMPs (TIMPs). The inhibitory
A great deal of progress has been made in our under-activity of TIMPs can be blocked by serine proteinases,
standing and treatment of crescentic glomerulonephritissuch as elastase [70].
since the times of Volhard and Fahr, and Ellis. This cate-The respiratory burst of activated neutrophils and
gory of glomerulonephritis, which was almost always fatal,monocytes generates oxidants, such as hypochlorous
now can be brought into sustained remission in many pa-acid, that can synergize with proteinases to lyse the GBM
tients. However, despite the steady incremental improve-[69, 70]. Stimulated glomerular epithelial cells and mes-
ments in the treatment of crescentic glomerulonephritisangial cells also can produce oxidants. Oxidants shield
serine proteinases from neutralization by serine protein- over the past 35 years, current toxic immunosuppressive
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regimens are far from ideal. As our knowledge of the response initiated the event. It means that by the time
pathophysiology of crescentic glomerulonephritis im- we biopsied and looked at the tissue, it contained mainly
proves, I am optimistic that a critical pathogenetic step T cells and macrophages. For example, in the model of
will be recognized and will be effectively targeted by ANCA disease caused by injection of anti-MPO IgG,
less-toxic therapeutic agents. even though the Rag 2 mice do not have T cell antigen
recognition capability, after the lesion evolves for 2
weeks, lymphocytes appear at the site of inflammation.QUESTIONS AND ANSWERS
In this model, anti-MPO IgG causes crescentic glomeru-
Dr. John T. Harrington (Dean, Tufts University lonephritis in the absence of T lymphocytes [48]. Thus,
School of Medicine, Boston, Massachusetts, USA): Let in some models, Th1 cells seem to be important, and in
me begin by asking a clinical question. Your second table others they are not.
showed a substantial difference in anti-GBM disease be- Dr. Annamaria Kausz (Division of Nephrology, New
tween African Americans and whites. What genetic dif- England Medical Center, Boston, Massachusetts, USA):
ferences might account for this finding? You spoke of the differences in outcomes of patients
Dr. Jennette: I do not think a specific explanation for with ANCA versus anti-GBM versus both. If you believe
this difference between African Americans and whites has
that the antibody itself is pathogenetic, why is the out-
been found. However, it is in line with other observations
come of those with both ANCA and anti-GBM antibod-of anti-GBM disease that clearly show a genetic predis-
ies better than that of those with only anti-GBM?position. There are human leukocyte antigen (HLA)
Dr. Jennette: It is difficult for me to understand whyphenotypes that are aligned with greater susceptibility
that is the case. To my knowledge, only one study hasfor anti-GBM disease. Fisher et al have clearly shown
documented that the prognosis is better with both [23].in humans and experimental models evidence for genetic
However, our own observations provide additional sup-susceptibility to anti-GBM disease [78]. This observation
port because we see an intermediate degree of injury,is in accord with the concept that cell-mediated immunity
not a greater degree when ANCA and anti-GBM aremight play an important role in anti-GBM disease in
both present (Table 4). The titer of the antibodies doeshumans as well as in animals because an HLA-associa-
not seem to be a factor. In our experience, both the anti-tion is consistent with a requirement for a particular kind
GBM and the ANCA titers are a little bit lower whenof antigen recognition capability and antigen display ca-
they are both together (Table 4), but other groups havepability. This capability could make certain patients sus-
not seen any difference.ceptible to anti-GBM disease. It may be that African
I must say that I do not understand the dual positivityAmericans lack this antigen presentation capability. To
at all. It would be easier to hypothesize what is goingmy knowledge, it has not been looked at in detail.
on if one came consistently before the other. If ANCADr. Harrington: In a recent New England Journal of
disease always came first and anti-GBM second, thenMedicine review, Schwartz discussed the observation that
you could say it was a disruption of the GBM by theknockout of T-bet, the gene for the transcription factor
ANCA disease that has engendered the anti-GBM re-that induces helper T cells to differentiate into Th1 cells,
sponse. But sometimes it is the other way around. I doaltered the distribution of T-helper 1 and 2 cells [79].
not understand that association at all.Have any studies looked at the subtypes of T-helper cells
Dr. Geetha Narayan (Division of Nephrology, St. Eliz-within the glomerular lesions?
abeth’s Medical Center, Brighton, Massachusetts, USA):Dr. Jennette: There have been a number of studies,
It was announced at the last American Society of Ne-most of which have supported the importance of Th1
phrology (ASN) meeting that a European study groupcells [80]. In fact, in the experimental models by Wu
had updated their studies of treatment for ANCA dis-et al [46], the injection of T-helper 1 cells specific for
ease. They were asked how long they were planning toGBM caused crescentic glomerulonephritis in mice. This
continue maintenance therapy in a specific patient andfinding supports the role for cell-mediated immunity in
hinted that it might be indefinite. Based on your under-crescentic glomerulonephritis. In all inflammation that
standing of the pathophysiologic mechanism and the pos-progresses from an acute to a chronic phase, an infiltra-
sible history, do you think that this is a disease that istion of lymphocytes orchestrates the inflammatory pro-
an unrelenting, chronic process that can be controlledcess as well as healing or scarring if required. However,
with indefinite therapy?T cell participation at the site of inflammation does not
Dr. Jennette: We are probably going to have to ex-necessarily mean that these cells were involved in initiat-
punge this answer because I am a pathologist! There ising the inflammation. In some types of glomerulonephri-
the empiric response, and then there is the hypotheti-tis, immunohistochemical evaluation reveals a predomi-
cal response based on what we think we know aboutnance of T cells and macrophages at some point in time,
but this does not prove that an antigen-specific T cell the pathogenesis. The empiric approach is to titrate the
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maintenance of remission against the toxicity from the the ones that we want to save. I think that current therapy
is directed more at neutrophils than at lymphocytes. Imaintenance therapy. As I said, if we give extensive im-
munosuppressive agents, there is still an approximately wonder whether the therapy that is most effective is not
the therapy that is most immunosuppressive, but the20% relapse within the first 3 years or so, and sometimes
as much as 50% if we don’t provide as much immunosup- therapy that reduces neutrophil and monocyte produc-
tion by the bone marrow.pression. For example, if you give a standard regimen,
you may have a 30% recurrence rate after remission, Dr. Andrew S. Levey (Division of Nephrology, New
England Medical Center): I am intrigued by your descrip-and you are worried about that 30%. You might want
to give more immunosuppressive agents for a longer tion of the publication of the induction of crescentic
glomerulonephritis by lymphocytes against the putativeperiod to obtain less recurrence. If you do that, it means
that 70% of the patients who were not going to have a antigen of anti-GBM disease [46]. I imagine that you are
trying to raise those kinds of lymphocytes in your MPOrecurrence will have been given more immunosuppres-
sion than they needed to protect the 30% who would knockout mice. Do you have any results to tell us about?
In particular, you downplayed the possibility that lym-have a recurrence. You might want to give maintenance
therapy until you reduce the recurrence rate to an accept- phocytes might injure GBMs. What causes people to
develop these autoantibodies and autoreactive lympho-able plateau and then give additional re-induction ther-
apy for recurrences. cytes?
Dr. Jennette: With respect to the model [48], the firstWith respect to the pathogenesis, I am concerned that
ANCA disease is a persistent disease. In contrast to anti- version that we created began with immunization of MPO
knockout mice with MPO and then transfer of their spleno-GBM, ANCA usually hangs around for a long time. We
might need some sort of long-term maintenance therapy cytes into the immune-deficient Rag 2 knockout mice.
We were using immune-deficient mice because we werefor ANCA disease, possibly something that can be di-
rected specifically toward the neutrophils and mono- transferring the immune system from the MPO knockout
mice to these mice. Of course, they adopted it. Withincytes.
Dr. Angelo A. Ucci, Jr. (Division of Pathology, New a few days, the anti-MPO titer in the recipient animal
reached the same level as in the donor animal. The TEngland Medical Center): Your suggestion that we inter-
vene during the early steps in the evolution of this injury cells and B cells take hold in the recipient mice. One
feature of that model might be a problem; it dependsis very interesting. My experience in looking at biopsies
is that early changes in the glomerulus are not terribly on your perspective. No matter what set of splenocytes
we transferred into the immune-deficient mice, whethercommon. I more often see the later stages of injury with
epithelial crescents and find areas of necrosis involving it was MPO knockout mice that were immunized with
nothing, MPO knockout mice immunized with bovinethe capillary walls. Has that been your experience? Have
you thought about ways that we might better ascertain serum albumin (BSA), or MPO knockout mice immu-
nized with MPO, when we transferred their immunethese injuries at an early stage?
Dr. Jennette: I think that earlier diagnosis will be systems into the immune-deficient mice, those mice de-
veloped mild immune-complex glomerulonephritis. Theyobtained in the clinical arena. General physicians need
to be more aware in their initial contacts with these all have clinically insignificant mesangial immune-com-
plex localization. Only the mice that receive the transferpatients, we need more rapid referral to nephrologists,
and diagnosis needs to be faster. Is there room for im- of anti-MPO–specific splenocytes develop glomerular
disease that is necrotizing and crescent forming and veryprovement? Once the diagnosis is made, we generally
are successful; most patients used to die of their disease, severe—90% of glomeruli with necrosis and crescents.
The next step was to dissect the pathogenetic process—but now most of them do not. With ANCA disease, in our
experience, only 50% of patients have 50% glomeruli transfer just anti-MPO antibodies, T lymphocytes, and
both. The easier of those two challenges was to transferinvolved with crescents. That means that 50% of the
patients whom we see have 50% or more of their glomer- just antibodies. We took serum from the knockout mice
that were immunized with MPO and isolated the IgG.uli without any crescents yet. Some might have segmental
necrosis. As a pathologist, I tend to home in on the most In the first experiment, we thought we were just going
to determine the titer based on passive transfer of IgGsevere lesions when I look at a specimen, and those are
the things that hold my attention. The European group so we could decide what dose to give. We never thought
that in the first experiment all five mice that receivedhas suggested that we pay attention to the glomeruli that
are not involved [81]. In fact, the percentage of uninvolved anti-MPO IgG would get necrotizing glomerulonephritis
[48]. As yet, we have not done experiments involvingglomeruli is the best prognostic indicator [40], which
leads to your point about how much injury exists in the transfer of T lymphocytes or T lymphtocytes plus anti-
MPO antibodies.beginning. I think that most patients have a reasonable
number of preserved nephrons, and those nephrons are Dr. Kausz: You mentioned the GBM and role of
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proteases, and how the proteases might be protected not see any difference in the pauci-immune necrotizing
from proteinase inhibitors by the microenvironment. glomerulonephritis that is ANCA-negative versus ANCA-
You alluded to an experiment in which proteinase inhibi- positive. However, having said that, I cannot see any
tors injected into mice protected them from necrotizing pathologic difference at the light microscopic level be-
glomerulonephritis [77]. Is this just a situation in which tween ANCA glomerulonephritis and anti-GBM glo-
you overwhelm the microprotection? merulonephritis. If the latter is shown to be cell-medi-
Dr. Jennette: The problem is delivery of antiprotein- ated, then I will have to adjust my thinking. I am still
ase to the site of the inflammation. Pharmaceutical com- holding on to the concept that anti-GBM antibodies are
panies are looking for antiproteinases as therapeutic pathogenetic in humans.
agents for asthma, arthritis, and other diseases where Dr. Gill: Would you comment on the prognosis and
there is a big market for anti-inflammatory agents. One management of this group of ANCA-negative patients
thing that is suspected, and in some instances docu- with pauci-immune disease?
mented, is that you need small molecules. The proteinase Dr. Jennette: There is no clinical or pathologic differ-
inhibitor we used was not a protein [77]. The naturally ence. They can have any of the phenotypes of ANCA-
occurring antiproteinases are pretty big molecules—they positive disease. They can have a clinical and pathologic
are proteins. If you could find a nontoxic, small-molecule expression of Wegener’s granulomatosis or microscopic
antiproteinase, it might be an effective treatment. The polyangiitis that is identical to what is seen in a patient
problem is that there are many biologically important who is ANCA-positive. Most patients with Churg-Strauss
proteinases. You have to be careful to come up with syndrome are ANCA-negative. Some people have con-
some therapeutic agent that can neutralize the ones that tended that this evidence indicates that ANCAs are not
you are concerned with without destroying the others. pathogenetic. Like all negative data, these data are less
Dr. Katrin Uhlig (Division of Nephrology, New En- powerful than the positive data that support a patho-
gland Medical Center): I am curious about the connection genetic role for ANCA. I am more confident now that
between anti-proteinases and ANCA disease. As you ANCA does cause disease in ANCA-positive patients.
know, genetic 1 antitrypsin deficiency might be associ- An alternative mechanism in ANCA-negative patients
ated with ANCA-positive glomerulonephritis [81]. Can might be causing the same pathologic phenotype and
we learn anything from the National Institutes of Health the same clinical phenotype. We treat all patients the
(NIH) studies of systemic 1 antitrypsin augmentation same whether they have ANCA-positive pauci-immune
therapy in patients with interstitial lung disease? glomerulonephritis or ANCA-negative pauci-immune
Dr. Jennette: I am not familiar with that study, but I glomerulonephritis.
think that any other inflammatory states showing benefit
Dr. Vaidyanatha Balakrishnan (Division of Ne-
from antiproteinase treatment would be worth looking
phrology, New England Medical Center): My questionat. There is an antiproteinase in the respiratory tract
relates to the role of antioxidants. Given the ability ofcalled secretory leukoproteinase inhibitor (SLPI), which
reactive oxygen species to inactivate proteinases, haveis an unusually small proteinase inhibitor. Some work
you any experience with anti-oxidants in the early phasehas been done using SLPI added to the respiratory tract
of animal studies?for local anti-inflammatory effects [82]. With lung dis-
Dr. Jennette: Even before we studied the mice withease, you are in a better position because you do not
immune-complex disease with the antiproteinase inhibi-have to get the antiproteinase into the circulation. The
tors back in the 1980s [77], we thought about using anti-problem with trying to treat glomerulonephritis or vascu-
oxidants in mice with glomerulonephritis. We did uselitis with proteinase inhibitors is that you have to put
superoxide dismutase in immune-complex models, andthem into the circulation and yet not interrupt important
we did see a reduction in severity of the disease, but thisserum cascades of homeostatic proteins such as the coag-
was published only as an abstract (abstract; Jennette JC,ulation cascade.
Fed Proc 41:325, 1982). A number of other studies inDr. John Gill (St. Paul’s Hospital, Vancouver, British
experimental models have shown that anti-oxidant ther-Columbia, Canada): Often we learn from the atypical
apy can reduce inflammation [83]. I think anti-oxidantscases. You mentioned a possible role for cell-mediated
are another possibility. It may be that we need to lookmechanisms of injury in anti-GBM disease. Could cellu-
for are additive effects—anti-oxidants plus antiprotein-lar mechanisms also be important in the group of patients
ases—because of the additive pathogenetic interactionwith pauci-immune disease who are ANCA-negative?
of oxidants and proteinases. Some studies have found aDr. Jennette: It is certainly possible. If most ANCA
reduction in the level of neutrophil activity in patientsdisease is antibody mediated, and now I am more con-
with ANCA disease who were given anti-oxidant vitaminvinced of that than in the past, and the remaining group
therapy [84]. I do not recall any correlation with anywas cell mediated, you would expect there to be some
subtle difference in the pathology, but there is not. I can- clinical parameters, but at least the first step has been
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basement membrane antibody-mediated glomerulonephritis duetaken to determine the effects of anti-oxidants on neutro-
to glue sniffing. Eur J Pediatr 146:296–300, 1987
phils in patients with ANCA disease. 14. Evans MD, Pryor WA: Cigarette smoking, emphysema, and dam-
age to alpha 1-proteinase inhibitor. Am J Physiol 266(6 Pt 1):L593–Dr. Harrington: What is the current approach at
L611, 1994Chapel Hill in patients who have achieved a remission
15. Niles JL, Bottinger EP, Saurina GR, et al: The syndrome of
from crescentic glomerular disease but who subsequently lung hemorrhage and nephritis is usually an ANCA-associated
condition. Arch Intern Med 156:440–445, 1996have rising serologies without evidence of clinical ac-
16. Saxena R, Bygren P, Rasmussen N, Wieslander J: Circulatingtivity?
autoantibodies in patients with extracapillary glomerulonephritis.
Dr. Jennette: There is a heightened sense of concern Nephrol Dial Transplant 6:389–397, 1991
17. Hagen EC, Daha MR, Hermans J, et al: Diagnostic value ofand alertness for further evidence of disease recurrence.
standardized assays for anti-neutrophil cytoplasmic autoantibodiesThe approach is not to treat the titer. The best evidence
in idiopathic systemic vasculitis. Kidney Int 53:743–753, 1998
supporting treatment based on titer is the work by Cohen 18. Lim LCL, Taylor JG, III, Schmitz JL, et al: Diagnostic usefulness
of antineutrophil cytoplasmic autoantibody serology: ComparativeTervaert et al in Europe [85]. They showed that if treat-
evaluation of commercial indirect fluorescent antibody kits andment begins when the titer begins to rise, patients have
enzyme immunoassay kits. Am J Clin Pathol 111:363–369, 1999
less recurrence of disease manifestations. In the long 19. Saxena R, Bygren P, Arvastson B, Wieslander J: Circulating
autoantibodies as serological markers in the differential diagnosisrun, patients treated on the basis of titer received less
of pulmonary renal syndrome. J Intern Med 238:143–152, 1995total immunosuppression because they had less recur-
20. O’Donoghue DJ, Short CD, Brenchley PE, et al: Sequential de-
rence than the group who were not treated on the basis velopment of systemic vasculitis with anti-neutrophil cytoplasmic
antibodies complicating anti-glomerular basement membrane dis-of ANCA titer who then required more immunosuppres-
ease. Clin Nephrol 32:251–255, 1989sion to bring their relapses under control. A number
21. Jayne DR, Marshall PD, Jones SJ, Lockwood CM: Autoantibod-
of studies, however, have shown very little correlation ies to GBM and neutrophil cytoplasm in rapidly progressive glo-
merulonephritis. Kidney Int 37:965–970, 1990between ANCA titers and recurrence. We are concerned
22. Vanhille P, Noel LH, Reumaux D, et al: Late emergence ofand vigilant when we see the ANCA titer rising, but we
systemic vasculitis with anti-neutrophil cytoplasmic antibodies in
do not treat on the basis of this finding alone. a dialyzed patient with anti-glomerular basement glomerulonephri-
tis. Clin Nephrol 33:257–258, 1990
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